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Jake S. O’Donnell1,2,3, Mark J. Smyth1,3† and Michele W. L. Teng2,3*†Editorial summary
Anti-programmed cell death 1 (PD1) immunotherapies
are among the most effective anti-cancer
immunotherapies available; however, a large number
of patients present with or develop resistance to
them. Unfortunately, very little is known regarding the
mechanisms of resistance to such therapies. A recent
study sought to identify mutations associated with
resistance to anti-PD1 therapy. Results from this study
demonstrated that mutations which affected the
sensitivity of tumor cells to T-cell-derived interferons,
and mutations limiting tumor-cell antigen presentation,
could cause acquired resistance. These findings have
significant implications for understanding the
mechanisms by which anti-PD1 therapies exert their
efficacy, comprehending why and how some patients
acquire resistance over time, and ultimately guiding the
development of combination therapies designed to
overcome, or potentially prevent, the development of
acquired immunotherapeutic resistance.many as 60 % of patients who receive it display primary
resistance [2]. More worryingly still, a recent studyCancer immunotherapy and immune checkpoints
Advances in cancer immunotherapy have resulted in re-
markable success in the treatment of a variety of human
cancers. Conceptual developments, such as the under-
standing that immune responses are routinely generated
against tumor-specific neoantigens (derived from pro-
teins mutated in the cancer) and that these responses
are usually limited by immunosuppressive tumor micro-
environments, have been key to the development of
immunotherapies capable of promoting immunological
control of tumor progression. Such therapies can act* Correspondence: michele.teng@qimrberghofer.edu.au
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ment features, or actively, by stimulating anti-tumor
immune responses. To date, therapies that block inhibi-
tory immunological signaling pathways (immune check-
points) promoted within tumor microenvironments have
demonstrated the greatest clinical benefit. The posterchild
for this success has been the use of monoclonal-antibody-
based therapies targeting the PD1 receptor upregulated on
activated T cells, or its ligands (programmed death ligands
1 and 2 (PD-L1 and PD-L2)), commonly upregulated by
tumor and tumor-associated immune cells. By limiting
this interaction, anti-PD1/PD-L1 therapy can release T
cells (primarily CD8+ T cells) from (or prevent the induc-
tion of) a state of functional exhaustion in which effector
functions are significantly diminished [1].Acquired resistance to anti-PD1/PD-L1 immunotherapy
Although anti-PD1/PD-L1 therapy is, to date, the most
effective single-agent therapy used in the treatment of
cancers such as melanoma, it has been shown that as
showed that approximately 25 % of melanoma patients
who demonstrated an objective response to anti-PD1
therapy developed acquired resistance, as characterized
by disease progression at a median follow-up of
21 months [3]. Unfortunately, few effective therapeutic
options are available for such patients, as very little is
known regarding the mechanisms by which acquired
resistance to anti-PD1/PD-L1 therapy occurs [4]. In a
recent edition of The New England Journal of Medicine,
some light was shed on this by Zaretsky and colleagues,
who sought to identify mutations associated with resist-
ance to anti-PD1 therapy [5]. Here, we discuss the
importance of this study, how its findings further our
understanding of acquired resistance to anti-PD1, and
its implications for the development of combination im-
munotherapeutic strategies.le is distributed under the terms of the Creative Commons Attribution 4.0
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genetic basis of resistance mechanisms
From a cohort of 74 melanoma patients, four were selected
who demonstrated an objective response to the anti-PD1
therapy pembrolizumab (also known as Keytruda; Merck),
who progressed after a median of 1.8 years despite
continuous therapy, and from whom tissue biopsies were
available at baseline (before therapy) and after disease pro-
gression. Initial responses to anti-PD1 therapy were associ-
ated with increased CD8+ T-cell infiltration within tumor
tissue. At relapse, however, CD8+ T cells were usually re-
stricted to the tumor margin. To identify a genetic basis for
the different phenotype of tumors at relapse, whole-exome,
next-generation sequencing was used to compare DNA iso-
lated from tumor cells derived from either biopsy material
or early passage cell lines obtained at baseline or at the time
of progression. It was revealed that two distinct pathways
were affected within different progressing lesions that lim-
ited the sensitivity of tumor cells to anti-tumor immunity.
Two patients were found to harbor loss-of-function
mutations within the genes encoding either Janus kinase
1 or 2 (JAK1 or JAK2), key intracellular signaling inter-
mediates necessary for sensitivity to T-cell-derived ef-
fector molecules known as interferons (IFNs). Mutations
were present at relapse and were accompanied by dele-
tion of the wild-type allele and duplication of the mutant
allele, leading to a two-copy loss of wild-type JAK.
Analyses revealed that resistant JAK-mutant cells were
derived from tumor cells clonally selected from those
present at baseline (Fig. 1). Functional characterization
was carried out in vitro, revealing that cells harboring
mutant JAK genes were capable of presenting antigen








Fig. 1 Clonal selection of occult tumor cells harboring T-cell resistance gen
colors represent intra-tumor heterogeneity with respect to genetic compos
mutations. b Tumor at maximum response. Although the bulk of the tumo
tumor cells harboring resistance genes are selected for, increasing the ratio
tumor is largely composed of cells containing resistance genes. In the abse
progression and metastasiscells. Interestingly, however, the sensitivity of the tumor
cells to T-cell-derived IFNs was dramatically decreased,
evidenced by reduced sensitivity to the anti-proliferative
effects of IFNs, decreased signal transducer and activator
of transcription 1 (STAT1) phosphorylation (an import-
ant transcription factor, phosphorylated by JAK1 and 2),
and reduced upregulation of major histocompatibility
complex (MHC) class I and PD-L1 in response to IFNs.
The second pathway shown to promote resistance to
anti-PD1 therapy was a familiar face [5]: a mutation
within the gene encoding β-2-microglobulin (B2M), the
protein product of which is necessary for the folding and
transport of MHC class I molecules to the cell surface
where they present antigen to T cells. This mutation was
shown to prevent the recognition of tumor antigen by
antigen-specific T cells.
Primary and acquired resistance to anti-PD1
therapy in other studies
This study very effectively demonstrated that like molecu-
larly targeted therapies, immunotherapies can select for
tumor cells resistant to pathways normally vulnerable to T-
cell-mediated assault in humans. This complements the
findings of others who have used mouse models to show
that acquired resistance to anti-PD1 therapy can develop by
non-genetic means, via upregulation of additional exhaus-
tion markers such as T-cell immunoglobulin mucin 3
(Tim3) [6]; however, it is not clear whether such effects will
be observed in human disease. Other studies investigating
resistance to anti-PD1 therapy have focused upon primary
resistance and have suggested that a number of factors can
promote T-cell resistance, such as poor tumor immunogen-
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vated PD1 expression on tumor-infiltrating T cells repre-
senting a state of severe functional exhaustion [1], and the
induction of alternative immunosuppressive pathways
within the tumor microenvironment [6], such as the release
of extracellular adenosine or indoleamine 2,3-dioxygenase
[1]. Importantly, the majority of these findings have been
made within mouse models and their relevance to human
cancers has yet to be comprehensively investigated.
Unanswered questions and future studies
The study conducted by Zaretsky et al. raises several in-
teresting questions. First, will patients with other cancer
types that respond to anti-PD1/PD-L1 develop acquired
resistance with similar mutations or pathways? Melano-
mas tend to have an extremely high mutational burden
in comparison with other tumor types, which could
logically reduce the chance that JAK or B2M mutations
might arise [7]. Second, are there ways of rescuing the
sensitivity of patients who acquire resistance to anti-PD1
therapy via these pathways? One approach, which was
investigated to a limited extent within the current study,
is the use of stimulator of interferon gene (STING)
agonists that are capable of promoting STAT activation
independent of JAK2 [5]. Another approach might be
the use of combination therapies that target tumor pro-
liferation while also promoting immune infiltration, such
as BRAF-targeted therapies or oncolytic viruses that
have been demonstrated to replicate preferentially within
cells with defective IFN signaling [9]. Third, could tumor
antigen-specific CD4 T cells, or innate cells such as NK
cells or myeloid cells, be targeted to promote anti-tumor
immunity in tumors harboring B2M mutations? Answer-
ing these questions will likely provide solutions to over-
come immunotherapeutic resistance.
So, is this checkmate? Is the game over for anti-PD1
therapies? Not in our opinion. Although immune check-
point inhibitors are only entering their adolescence, they
are currently proving to be without doubt the most
effective therapeutic option available to promote anti-
tumor immunity. Immunotherapies will become a main-
stay of cancer treatment, so understanding resistance is
extremely important, but we need to know more before
we make our next move. Given that three out of the four
patients screened within this study harbored different
mutations (within two separate pathways), it seems
highly likely that additional studies with larger cohort
sizes might identify alternative causative pathways. The
findings of such studies, when coupled with tumor-
immune profiling, could be of great benefit in a predict-
ive context to stratify patients based upon likelihood of
response and to guide the rational application of com-
bination therapies. We have seen one good move. It is
now up to us to look for the next one.Authors’ contributions
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